glp vs semaglutide vs. Tirzepatide: Which GLP-1 Wins? GLP-1 medications are marketed to

Liver stiffness measured by vibrationcontrolled transient elastography (VCTE) revealed that 52.0% of semaglutide patients achieved 30% reduction versus 30.3% of placebo recipients

The medicine is being marketed under the brand name Lirafit after receiving approval from the medicine Controller General of India (DCGI)

Eligible beneficiaries contribute a $50 monthly copay, making the total out-of-pocket cost dramatically lower than commercial pricing

Slower gastric emptyinghow the stomach processes foodis the mechanism behind these effects, and they typically diminish within 24 weeks as the body adapts

But the insulin sensitization effects of tirzepatide likely contribute independently, since improvements in hormonal markers sometimes precede significant weight change

In some analyses, early initiation is associated not merely with neutral cardiovascular outcomes but with active cardiovascular benefit, a finding that aligns with the known role of estrogen in maintaining vascular elasticity, endothelial function, and lipid metabolism [12]